GZ
Gerhard Zugmaier
Georgetown Lombardi Comprehensive Cancer Center, University of Tübingen, National Cancer Institute
Research areas: Medicine · Hematology · CAR-T cell therapy research · Acute Lymphoblastic Leukemia research · Lymphoma Diagnosis and Treatment
0000-0001-6879-2671
Employment
Employment history is unavailable.
Education
-
Georgetown Lombardi Comprehensive Cancer Center Fellow of Medicine
-
National Cancer Institute Fellow
Projects & Funding
Projects & funding information is unavailable.
Publications (14)
- Transient and fully reversible changes in laboratory parameters and modifications of the cytokine profile during blinatumomab treatment in children with relapsed or refractory B‐cell acute lymphoblastic leukemia Save
- Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL Save
- Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study Save
- Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study Save
- Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia Save
- Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis Save
- CD19 expression in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia pre‐ and post‐treatment with blinatumomab Save
- Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save
- Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save
- Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab Save
- Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save
- Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save
- Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save
- Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Save